Using aggregated, de-identified electronic health record data for multivariate pharmacosurveillance: A case study of azathioprine  by Patel, Vishal N. & Kaelber, David C.
Journal of Biomedical Informatics 52 (2014) 36–42Contents lists available at ScienceDirect
Journal of Biomedical Informatics
journal homepage: www.elsevier .com/locate /y jb inUsing aggregated, de-identiﬁed electronic health record data
for multivariate pharmacosurveillance: A case study of azathioprine1532-0464/$ - see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jbi.2013.10.009
Abbreviations: AZA, Azathioprine; EHR, electronic health record.
⇑ Corresponding author. Address: Center for Proteomics and Bioinformatics,
10900 Euclid Ave., BRB 9th Floor, Case Western Reserve University, Cleveland, OH
44106, United States.
E-mail address: vishal.patel2@case.edu (V.N. Patel).Vishal N. Patel a,b,⇑, David C. Kaelber a,c,d,e,f
aCenter for Clinical Informatics Research and Education, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States
bCenter for Proteomics and Bioinformatics, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States
cDepartments of Information Services, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States
dDepartment of Internal Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States
eDepartment of Pediatrics, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States
fDepartments of Epidemiology and Biostatistics, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States
a r t i c l e i n f o a b s t r a c tArticle history:
Available online 28 October 2013
Keywords:
Clinical research informatics
De-identiﬁed data
Systems biology
Postmarketing drug surveillance
Pharmacosurveillance
AzathioprineObjective: To demonstrate the use of aggregated and de-identiﬁed electronic health record (EHR) data for
multivariate post-marketing pharmacosurveillance in a case study of azathioprine (AZA).
Methods: Using aggregated, standardized, normalized, and de-identiﬁed, population-level data from the
Explore platform (Explorys, Inc.) we searched over 10 million individuals, of which 14,580 were pre-
scribed AZA based on RxNorm drug orders. Based on logical observation identiﬁers names and codes
(LOINC) and vital sign data, we examined the following side effects: anemia, cell lysis, fever, hepatotox-
icity, hypertension, nephrotoxicity, neutropenia, and neutrophilia. Patients prescribed AZA were com-
pared to patients prescribed one of 11 other anti-rheumatologic drugs to determine the relative risk of
side effect pairs.
Results: Compared to AZA case report trends, hepatotoxicity (marked by elevated transaminases or ele-
vated bilirubin) did not occur as an isolated event more frequently in patients prescribed AZA than other
anti-rheumatic agents. While neutropenia occurred in 24% of patients (RR 1.15, 95% CI 1.07–1.23), neu-
trophilia was also frequent (45%) and increased in patients prescribed AZA (RR 1.28, 95% CI 1.22–1.34).
After constructing a pairwise side effect network, neutropenia had no dependencies. A reduced risk of
neutropenia was found in patients with co-existing elevations in total bilirubin or liver transaminases,
supporting classic clinical knowledge that agranulocytosis is a largely unpredictable phenomenon.
Rounding errors propagated in the statistically de-identiﬁed datasets for cohorts as small as 40 patients
only contributed marginally to the calculated risk.
Conclusion: Our work demonstrates that aggregated, standardized, normalized and de-identiﬁed popula-
tion level EHR data can provide both sufﬁcient insight and statistical power to detect potential patterns of
medication side effect associations, serving as a multivariate and generalizable approach to post-market-
ing drug surveillance.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Azathioprine (AZA), a purine analog widely used in solid organ
transplants and autoimmune disorders, is known to induce a spec-
trum of toxicities. While bone marrow suppression [1,2] and hep-
atotoxicity [3] – thought to be dose-dependent effects due to the
accumulation of 6-thioguanine metabolites – are the most widely
recognized side effects, dermatologic [4] and renal effects [5] havealso been reported. Predictions of adverse reactions can be guided
by thiomercaptopurine methyltransferase (TPMT) activity [6,7],
though TPMT activity has poor sensitivity as a test for toxicity
[8]. As a supplement to measuring TPMT activity, case reports of
AZA’s toxicities help document the clinical course of side effects,
yet the likelihood of a particular organ system’s involvement is of-
ten established on an ad hoc basis from a survey of the literature.
Consequently, side effects with a poor showing in the literature are
presumed to be rare, though they may, in fact, be common. More
generally, tracking side effects via case reports or reporting dat-
abases provides inaccurate and incomplete estimates of incidence.
While case reports and TPMT activity help to substratify pa-
tients into cohorts likely to develop adverse reactions, clinical
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sets of clinical patterns that arise in patients prescribed AZA.
Studying multivariate side effects allows for a syndromic approach
to identifying adverse drug reactions, which can point to clinical
patterns for gauging a subgroup’s risk of developing complications.
While knowledge of disease presentations and syndromes was
classically acquired through prolonged clinical observations, the
emergence of electronic health data sources now allow for the pos-
sibility of mining such information through retrospective data
analysis, based on data captured as part of routine clinical care.
In particular, network models have proven useful in mining and
organizing patterns of clinical phenomena, with recent applica-
tions in the assembly of disease comorbidity networks based on
frequencies of ICD-9 (International Classiﬁcation of Diseases, ninth
revision) code co-occurrence [9,10]. These networks of side effects
provide a global overview of disease-disease associations and may
be useful for lifetime risk calculations, though they have limited
utility in informing clinical practice as they lack temporal associa-
tions and speciﬁc clinical variables. Additionally, there may be sig-
niﬁcant issues with the accuracy of ICD-9 codes. In the area of
pharmacosurveillance, research has classically focused on signal
detection from voluntary reporting databases, which are limited
by the biases inherent in voluntary submissions of adverse drug
event [11]. Methodologically, pharmacosurveillance has largely fo-
cused on the extraction of bivariate – i.e. drug-event – signals
[11,12], though studies have recently emerged that focus on
detecting multivariate patterns through association rule mining
[13,14].
In this work, we aim to (1) quantify the incidence of size effects
associated with AZA, (2) compare the incidence of side effects asso-
ciated with AZA to other similar drugs, and (3) combine network-
based approaches with traditional pharmacosurveillance signal
detection methods to discover patterns of multiple events associ-
ated with AZA that can be clinically informative. As opposed to dis-
covering events in reporting databases, we used a database of
aggregated, standardized, normalized, and de-identiﬁed popula-
tion level EHR data from over 10 million patients. Rather than
using ICD-9 codes, we use laboratory and vital sign measurements
– reliable ﬁelds in most EHR systems [15] – to assess the presence
of side effects. The use of laboratory and vital sign values from
aggregated EHR data avoids the biases of spontaneous reporting
systems and the problems with provider-entered ICD-9 codes,
while simultaneously increasing our power to detect rare event
associations.2. Materials and methods
2.1. Database description
De-identiﬁed data was obtained using the Explore application
of the Explorys platform (Explorys, Inc.), which places a health data
gateway (HDG) server behind the ﬁrewall of each participating
healthcare organization. After collecting data from a variety of
health information systems – electronic health records (EHRs), bill-
ing systems, laboratory systems, etc. – the HDG maps the data to
informatics ontologies, standardizing and normalizing measure-
ments. Next, the data from each participating healthcare organiza-
tion is passed into a data grid. A web application allows each
healthcare organization to search and analyze the aggregated,
standardized, normalized, and de-identiﬁed population level data.
At the time of this study, the aggregated data grid contained
information on more than 10 million patients from multiple, dis-
tinct healthcare systems with different EHRs; the EHR serves as
the primary medical record within participating institutions. All
data used were de-identiﬁed to meet Health Insurance Portabilityand Accountability Act (HIPAA) and Health Information Technol-
ogy for Economic and Clinical Health (HITECH) Act standards.
Therefore, this work was deemed not to be human studies research
by the Institutional Review Board of the MetroHealth System. Busi-
ness afﬁliation agreements were in place between all participating
healthcare systems and Explorys Inc. regarding contribution of
EHR data and the use of these de-identiﬁed data. Uniﬁed Medical
Language System (UMLS) ontologies were used to map EHR data
to facilitate searching and indexing. Diagnoses, ﬁndings, and proce-
dures were mapped into the systematized nomenclature of medi-
cine-clinical terms (SNOMED-CT) hierarchy [16]. Prescription
medication orders were mapped to RxNorm [17]. Laboratory test
observations were mapped to logical observation identiﬁers names
and codes (LOINC), established by the Regenstrief Institute [18]. At
the time of analysis, the application contained 14,580 records of
patients who had ever been prescribed AZA.
2.2. Side effect network analysis
Our analysis focused on end-organ dysfunction known to be
implicated with AZA, as well as non-speciﬁc side effects, such as
hypertension, fever, and cell lysis. To study side effect patterns of
AZA associated with particular organ systems, we used key refer-
ence ranges for lab values as proxies of organ function (Table 1)
[19].
Patients were selected who had normal lab values within
90 days prior to being prescribed AZA, and an abnormal measure-
ment within 90 days after being prescribed AZA. As the actual
administration or consumption of a medication is often not re-
corded in EHRs, especially for outpatient medications, we used
medication orders as a proxy for drug administration (i.e. the term
‘‘prescribed’’ refers to the date at which the order for ‘‘azathio-
prine’’ appeared in the patient’s EHR). For neutropenia and neutro-
philia, we extended the selection window to patients with a
normal neutrophil count within 365 days prior to AZA prescription.
To avoid inﬂating the signiﬁcance of creatinine measurements due
to subgroup effects from pre-existing renal dysfunction, we ex-
cluded all patients with an ICD-9 or American Medical Association
Common Procedural Terminology (CPT) code mapped to any of the
following SNOMED terms: renal impairment, renal failure
syndrome, history of kidney transplant, or renal transplant
(procedure).
2.3. Control cohort
Identiﬁcation of patients suffering from various side effects is
subject to the myriad biases of dealing with EHR data. For instance,
an elevation in blood pressure observed after prescribing AZA may
be due to external factors (e.g. environment, other drugs) or errors
in measurement. Similarly, an elevation in liver enzymes may sim-
ply be a phenomenon associated with the underlying autoimmune
disease rather than AZA. To address these issues and to calculate
the signiﬁcance of AZA-induced side effects, we assembled a con-
trol cohort of patients who experienced abnormal values when
administered one of 11 other anti-rheumatic drugs (Table 2). The
control drugs were identiﬁed by ﬁrst selecting those drugs tagged
with the SNOMED (Systemized Nomenclature of Medicine) code
‘‘anti-rheumatic agents.’’ This unﬁltered list of 42 drugs contains
agents with both frequent and infrequent side effect proﬁles, and
the inclusion of drugs with infrequent side effects would artiﬁcially
inﬂate the signiﬁcance of side effects associated with AZA. Apart
from identifying statistically signiﬁcant side effects, we also sought
to identify clinically relevant side effects. In this regard, it was
important to account for the prevalence of ‘‘common’’ side effects,
e.g. headache, to judge the relevance of side effects associated with
AZA. Thus, to avoid statistical bias and produce clinically relevant
Table 1
Side effects assessed after AZA prescription.
Side effect Lab value Abnormal range
Anemia Hemoglobin (Hgb) <11 g/dL
Cell lysis Lactate dehydrogenase (LDH) >190 IU/L
Fever Temperature >37.8 F
Hepatotoxicity Aspartate aminotransferase
(AST), Alanine aminotransferase
(ALT)
AST > 40 IU/L and
ALT > 40 IU/L
Hepatotoxicity Total bilirubin (Bili) >1 mg/dL
Hypertension Blood pressure (BP) Systolic > 140 mm Hg
or
Diastolic > 90 mm Hg
Nephrotoxicity Creatinine (Cr) >1.5 mg/dL
Neutropenia Neutrophil count Count < 57% or
<2.5 cells/ll
Neutrophilia Neutrophil count Count > 70%
Table 2
Distribution of anti-rheumatic agents among the control and AZA cohorts.
Drug name (RxCUI) Control cohort (% Total) AZA cohort (% Total)
Abatacept (614391) 180 (0.2%) 80 (0.5%)
Adalimumab (327361) 3100 (4.3%) 750 (5.1%)
Azathioprine (1256) 3330 (4.6%) 14,270 (97.9%)a
Clioquinol (5942) 100 (0.1%) 0 (0.0%)
Etanercept (214555) 2920 (4.0%) 280 (1.9%)
Hydroxychloroquine (5521) 27,670 (38.3%) 2120 (14.5%)
Inﬂiximab (191831) 3100 (4.3%) 1320 (9.1%)
Iodoquinol (3435) 5510 (7.6%) 50 (0.3%)
Leﬂunomide (27169) 1620 (2.2%) 520 (3.6%)
Methotrexate (6851) 21,000 (29.0%) 1880 (12.9%)
Oxyquinoline (110) 280 (0.4%) 0 (0.0%)
Sulfasalazine (9524) 6230 (8.6%) 630 (4.3%)
Total 72,290 14,580
a The fraction of patients in the AZA cohort prescribed AZA is not 100% since this
analysis was performed at a different time than the side effect network analysis.
The analysis tool maps patients to the most current instantiation of the patient
database, and a discrepancy indicates a change in the underlying database between
analyses.
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fects. Namely, we selected the subset of anti-rheumatic drugs for
which at least 5% of all patients prescribed the drug were tagged
with the SNOMED code ‘‘Adverse Reaction to Drug’’ and at least
50% were tagged with a SNOMED ‘‘Allergy to Drug’’ code. This ap-
proach does not guarantee that a particular drug was responsible
for an adverse reaction or a drug allergy; rather, it serves to in-
crease the likelihood of a drug-event association. We also included
sulfasalazine, for whom 49.4% of patients prescribed the drug had
an ‘‘Allergy to Drug’’ code. Through this process, we arrived at a
concise list of 12 anti-rheumatic agents that are prone to inducing
toxicity. After manual inspection of this list, homatropine was ex-
cluded because it is applied topically, rather than taken orally, to
treat rheumatologic sequelae (i.e. uveitis). Overlap is evident be-
tween the ‘‘AZA’’ and ‘‘non-AZA’’ cohorts since controlling the
AZA cohort for the absence of the other 11 drugs was computation-
ally intractable and yielded cohorts of near-null size, as most pa-
tients prescribed AZA have also been prescribed other anti-
rheumatic agents at some point.
We performed database searches for subsets of patients experi-
encing each of the 9 individual side effects (Table 1) and the 36
non-redundant side effect pairs. As over-constraining the search
resulted in too few patients, searches were not designed to be
mutually exclusive, i.e. a search for patients with abnormal creat-
inine and abnormal bilirubin was not controlled to rule out those
patients with abnormal hemoglobin, abnormal blood pressure,etc. The total number of patients experiencing each individual side
effect and each side effect pair is shown in Supplemental Table 1.
For the AZA group experiencing two side effects, cohort sizes ran-
ged from 10 to 310 patients. Control cohort sizes ranged from 70 to
1400 patients. We also calculated the number of patients with nor-
mal laboratory and vital sign values before and after drug prescrip-
tion. This value was used in calculating the total number of
patients in whom the value was measured, which was necessary
for estimating the proportion of patients experiencing a single side
effect.
2.4. Side effect network
As with previous network models of disease co-occurrence
[9,10], we began construction of our network by compiling the fre-
quencies of side effect pairs. To help identify causal relationships
between side effects, we then calculated the conditional probabil-
ity of developing a side effect, as per Bayes’ theorem:
PðAjBÞ ¼ PðA \ BÞ
PðBÞ ð1Þ
where A and B represent two abnormal values for two side effects.
To reduce the number of pairwise searches required, we simpliﬁed
the probability as follows:
PðAjBÞ ¼ #ðA \ BÞ=#ððA \ BÞ [ ðA \ BÞÞ
#B=#ðB [ BÞ 
#ðA \ BÞ
#B
ð2Þ
where #ðA \ BÞ represents the number of patients with abnormal
values for both A and B, and #ðB [ BÞ represents the total number
of patients with either an abnormal or normal value for B. The
right-hand side approximation is possible if the total number of pa-
tients in the denominator of P(B) is similar to the total number for
the numerator, PðA \ BÞ. We found this to be true for our data,
where both denominators were of similar order. To normalize the
probability of AZA event associations by an appropriate back-
ground, we calculated the relative risk of a side effect association
in the AZA cohort relative to the control cohort, assessing signiﬁ-
cance using the 95% conﬁdence interval. This approach is akin to
the proportional reporting ratio commonly used in pharmacovigi-
lance [11]. Cells in Table 3 are color-coded according to the relative
risk induced by AZA relative to the control drugs.
2.5. Error propagation analysis
Since cohort numbers reported were rounded to the nearest ten
(for full statistical de-identiﬁcation), we calculated the uncertainty
propagated by this rounding error. Since the relative risk is based
on divisions of proportions, we estimated the error carried forth
in division (or multiplication) of two proportions, z = x/y, as:
Dz
z
 2
¼ Dx
x
 2
þ Dy
y
 2
ð3Þ
where Dx and Dy are the uncertainty in the proportions x and y,
respectively, and Dz is the uncertainty in the relative risk [20].
The uncertainties of x and y are both equal to 5 in this case (as co-
hort sizes were rounded to the nearest 10). The contribution of
rounding error to the relative risk is reported in Table 4.
3. Results
3.1. Incidence of individual side effects
The proportion of patients experiencing side effects 90 days
after prescription of AZA appears in Table 3. Side effect pairs with
an increased risk of co-occurrence under AZA are highlighted, with
Table 3
Frequencies and conditional probabilities of side effects induced by AZA.
aThe diagonal represents the proportion of patients experiencing a single side effect. The off-diagonal elements represent the conditional probability, P(column|row).
bThe relative risk of developing a side effect pair (relative to any one of 12 anti-rheumatic drugs) is indicated by the cell color; only those side effect pairs with a statistically
signiﬁcant (95% conﬁdence interval) increased risk are highlighted.
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one of the 11 other anti-rheumatic drugs. Proportions were calcu-
lated relative to the side effect on the row, P(column|row). For each
row, the proportion of AZA patients suffering from that individual
side effect (along the diagonal) is calculated relative to the total
number of patients given AZA that had this particular laboratory
or vital sign value measured, i.e. normal and abnormal combined.
While a single laboratory or vital sign measurement may not have
been identiﬁed as occurring more frequently in AZA patients, the
frequency may be increased when viewed in conjunction with
other laboratory or vital sign values, and these pairings are found
in the off-diagonal elements of Table 3.
Among isolated lab or vital sign values along the diagonal of
Table 3, we ﬁrst note that renal dysfunction (measured by ele-
vated creatinine) is infrequent, with only 7.9% of patients devel-
oping a measured creatinine having an abnormal value (i.e.
>1.5 mg/dL). The relative risk of nephroxicity in patients pre-
scribed AZA was not statistically signiﬁcantly greater than pa-
tients prescribed other anti-rheumatic drugs (RR 1.19, 95% CI
0.99–1.44). The proportion of patients suffering from hepatotox-
icity as measured by either elevated transaminases or bilirubinTable 4
Contribution of rounding error to uncertainty in relative risk.
aUncertainties greater than 0.10 are highlighted in gray; this cu
signiﬁcant digits.
bTwo cells marked as ‘‘not a number’’ (NaN) had cohorts too sm
cNeutrophilia and neutropenia are mutually exclusive.was 14.1%. However, neither elevated transaminases (RR 0.99,
CI 0.86–1.14) nor an elevated bilirubin (RR 1.01, CI 0.88–1.16)
occur as isolated events more frequently in patients prescribed
AZA than other anti-rheumatic agents in our data. AZA-associ-
ated fever, deﬁned in our study as a temperature >37.8 C, oc-
curred at a rate of 13.1% of AZA patients (RR 1.31, CI 1.18–
1.44), more than three times the previously reported incidence
of fever of 4.2% [21].
Given AZA’s well-known side effect of bone marrow suppres-
sion, we successfully identiﬁed the signiﬁcantly increased risk of
neutropenia in 24% of AZA users (RR 1.15, CI 1.07–1.23). Anemia
is highly prevalent (28%) in our cohort, but AZA does not demon-
strate an increased risk relative to other anti-rheumatic drugs
(RR 0.97, CI 0.90–1.05).
Neutrophilia, thought to arise either in direct response to the
drug or from bone marrow stimulation due to excessive hemolysis
[4], was also frequent (45.2%) and signiﬁcant (RR 1.28, CI 1.22–
1.34). Among the non-speciﬁc laboratory and vital sign values
(temperature, blood pressure, and lactate dehydrogenase), over a
quarter (30%) of patients experienced a spike in blood pressure
after being prescribed AZA, equivalent to controls (RR 1.01, CItoff was chosen because the smallest cohort size was two
all to report and were estimated as zero.
Fig. 1. AZA-induced side effect network showing links with signiﬁcantly increased
risk relative to other anti-rheumatic drugs. Lab measurements highlighted in green
have an increased risk for occurrence in patients prescribed AZA; gray nodes have a
decreased or non-signiﬁcant risk. The size of a node corresponds to the proportion
of patients experiencing that side effect. Edge widths are scaled to the proportion of
AZA patients experiencing the side effect pair; edge color corresponds to relative
risk. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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(59%) of patients prescribed AZA experience a rise in LDH, for
which the risk may be marginally more signiﬁcant than other
anti-rheumatic agents (RR 1.15, CI 1.00–1.34).
3.2. Side effect network
The off-diagonal proportions in Table 3 approximate condi-
tional probabilities, and, thus, the side effect matrix can be viewed
as a directed graph, or network (Fig. 1). In the side effect network,
the preponderance of inputs into LDH characterizes it as a down-
stream ‘‘sink’’: a clinical phenomenon whose existence is condi-
tional on several priors. As expected based on the large
proportion of patients experiencing neutrophilia, this non-speciﬁc
side effect also acts as a sink in the network. Neutropenia and ele-
vated transaminases are both disconnected from the other side ef-
fects in the network, indicating that, by this approach, these two
side effects have no reliable priors upon which clinical predictions
can be made. In particular, neutropenia had a signiﬁcantly reduced
risk of occurrence in association with several network variables:
elevated transaminases (RR 0.34, CI 0.22–0.52); elevated bilirubin
(RR 0.33, CI 0.21–0.51); fever (RR 0.54, CI 0.39–0.74); elevated
blood pressure (RR 0.74, CI 0.58–0.94); and anemia (RR 0.49, CI
0.38–0.62).
3.3. Error propagation
We calculated how rounding of cohort sizes – part of the
statistical de-identiﬁcation process – may propagate error
throughout the analysis, and these results are shown in Table 4,
with uncertainties greater than 0.1 highlighted. With the large
cohort sizes available for single abnormal laboratory and vital
sign searches (e.g. a creatinine elevation alone), the uncertain-
ties introduced by rounding error are small and noncontribu-
tory along the diagonal. As expected, the small size of
cohorts in whom an abnormal LDH was measured resulted in
a high degree of uncertainty in the relative risk calculated.
For each side effect pair, the conﬁdence interval based on sam-
pling error was larger than the interval spanned by rounding
error.4. Discussion
In this work, we illustrate how exploration of a side effect
network using aggregated, standardized, normalized, and de-
identiﬁed population level EHR data can yield clinically useful
patterns for detecting post-marketing drug-side effect associa-
tions. In our case study of AZA, we assembled a subset of labo-
ratory and vital sign measurements from aggregated EHR data,
and, after calculating conditional probabilities of co-occurrence,
compiled a subnetwork of side effects more frequently associ-
ated with AZA than with other anti-rheumatologic drugs. In
quantifying overall side effects associated with AZA, we found
that nephrotoxicity is a rare event (7.9%) that does not occur
more frequently in AZA patients than in patients prescribed
other anti-rheumatologic agents studied. We also found that
our estimated rate of neutropenia is comparable to the rate re-
ported by Salix Pharmaceuticals, Inc. for leukopenia (28%) in
rheumatoid arthritis [23]. Neutropenia and/or leukopenia have
been previously reported at much lower rates, from 2.9% [24]
to 5.5% [25] to 10.5% [21], and the higher incidence of this side
effect in our study may be due, in part, to the conservative cut-
off used to deﬁne the clinical event. In addition, the total num-
ber of patients (i.e. the denominator) used for our calculations is
based upon patients in whom neutrophils were measured but
were found to be normal. Since a neutrophil count was ordered
in these patients as part of routine clinical care, the clinician
may have been suspecting an abnormality of this laboratory va-
lue, and, thus, this subgroup of patients with a ‘‘normal’’ neutro-
phil count may artiﬁcially underestimate the true proportion of
patients whose neutrophils were unaffected by AZA.
An elevated neutrophil fraction in AZA has received mixed
attention over the years, playing a prominent role in a recent der-
matologic review [4], while receiving no mention in other case re-
ports [5,26,27]. As a downstream clinical phenomenon, or sink, this
ﬁnding may have received scant attention [28] for its lack of spec-
iﬁcity and ambiguous biological role. However, our ﬁndings clearly
show that both neutrophilia and neutropenia are relatively fre-
quent entities with distinct patterns uniquely associated with
AZA prescriptions.
We also found that elevated liver transaminases are no more
frequent in patients prescribed AZA (14.1%) than in patients pre-
scribed other anti-rheumatic agents, contrary to reporting trends
[26]. This is similar to the rate (13.7%) reported in a pediatric pop-
ulation based on an AST greater than twice normal limits [21],
though our incidence is much greater than the rate (5.2%) found
by Hindorf et al. [25].
The use of a side effect network allowed us to examine the
interplay between organ systems that show differential involve-
ment in the process of AZA toxicity. In particular, we recapitulated
the classic clinical knowledge that neutropenia is, indeed, an
unpredictable event, as it has no dependencies in our side effect
network. Though a lack of statistically signiﬁcant associations
alone does not prove the absence of such associations, neutropenia
also had a decreased and statistically signiﬁcant relative risk of
association with several side effects, supporting our claim that pat-
terns of neutropenia are isolated and distinct from other variables
examined in our study. Thus, our analysis has the power to segre-
gate side effects by our ability to predict and prevent them. In the
future analysis of drug side effects, our work would allow biomed-
ical researchers to limit their scope to clinically unpredictable side
effects in order to identify molecular bases for prevention and ther-
apy (e.g. the role of TPMT in predicting bone marrow toxicity in
AZA).
As mentioned, there may be confounders in the underlying data
set that may systematically bias our AZA results. Importantly, the
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must proceed with caution, as such correlations are signiﬁcantly
inﬂuenced by selection bias. For instance, we found that inclusion
of renal transplant patients in our analysis – approximately 10% of
our AZA cohort – produced a signiﬁcant interaction between creat-
inine elevation and anemia in our side effect network, which may
be attributable to hemolytic uremic syndrome following renal
transplant [29] rather than AZA prescription per se. These kinds
of issues reﬂect underlying clinical heterogeneities that may be dif-
ﬁcult to deduce at the aggregate level [30]. In another example,
LDH is not a routine laboratory order; it is more frequently ordered
in intensive care units and by physicians who suspect a hemolytic
process. Consequently, patient cohorts exhibiting correlations be-
tween LDH and other side effects may signiﬁcantly differ in their
clinical characteristics from patient cohorts exhibiting correlations
between routine measurements (e.g. blood pressure and tempera-
ture). While individual correlations, or edges, are prone to such
selection bias, the global structure of the side effect network re-
ﬂects generalizable processes, reﬂected in the network’s ability to
recapitulate classic clinical knowledge. Our careful choice of con-
trols based on patients’ prescribed medications of the same phar-
macological class also serves to minimize concerns of selection
bias. The appropriate selection of controls and the reduction of co-
hort heterogeneity remain open questions in the analysis of aggre-
gated, de-identiﬁed, population-level data. Additionally, we
recognize that there is cross-contamination between the AZA and
control cohorts. While this cross-contamination biases the results
toward the null hypothesis, we continued to ﬁnd statistically sig-
niﬁcant results between the two groups. Finally, while the round-
ing error introduced for statistical de-identiﬁcation appears
formidable, we show that the error introduced for cohorts as small
as 40 patients is often only a marginal contribution to the calcu-
lated relative risk (Table 4).
Our work lays the foundation for future explorations of side ef-
fect networks using pooled, standardized, normalized, and de-
identiﬁed population level EHR data. As opposed to the ‘‘global’’
networks assembled in recent studies [9,10] from ICD-9 codes,
we illustrate the power of ‘‘local’’ networks focusing on a few,
well-deﬁned clinical parameters, based on LOINC or vital sign data.
Using the methodology outlined herein, we show that side effect
networks can be leveraged to increase post-marketing surveillance
of drugs and associated side effects. While this work examined the
effects of AZA retrospectively over more than a decade, periodic
assessments of EHR data would allow the AZA side effect network
(or side effect networks for other drugs) to proactively track clini-
cal phenomena, with increasing statistical power as more EHR data
becomes available. The approach presented here identiﬁes associ-
ations between prescribed medications and side effects and points
to areas to investigate further to understand if true cause and effect
exist. The tools and methodologies used here are also very scalable
to many other medications and side effects that could be explored
for post-market drug surveillance.
This case study of AZA demonstrates the growing potential of
clinical research informatics tools and methodologies to address
important clinical questions. As digital clinical data becomes
increasingly available through the proliferation of EHRs, the possi-
bilities for the secondary use of such data are numerous, though
contingent upon the development of new tools and methods. Our
example for post-marketing drug surveillance demonstrates that
clinical research informatics combining the right clinical data
(large aggregated, standardized, normalized, and de-identiﬁed
EHR data), the right tools (a fast, easy-to-use, and HIPAA/HITECH
compliant interface), and the right methods (side effect analyses
driven by case reports and biological hypotheses) has the ability
to transform certain types of clinical research, in this case post-
marketing drug surveillance.Conﬂict of Interest
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